नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

astrazeneca b.v prinses beatrixlaan 582 2595 bm den haag - quetiapinefumaraat 230,26 mg/stuk samenstelling overeenkomend met ; quetiapine 200 mg/stuk - tablet met verlengde afgifte - cellulose, microkristallijn (e 460(i)) ; hypromellose (e 464) ; hypromellose (release controlling polymer)(e 464) ; ijzeroxide geel (e 172) ; lactose 1-water ; macrogol 400 ; magnesiumstearaat (e 470b) ; titaandioxide (e 171) ; trinatriumcitraat 2-water (e 331), cellulose, microkristallijn (e 460) ; hypromellose (e 464) ; hypromellose (release controlling polymer)(e 464) ; ijzeroxide geel (e 172) ; lactose 1-water ; macrogol 400 ; magnesiumstearaat (e 470b) ; titaandioxide (e 171) ; trinatriumcitraat 2-water (e 331), - quetiapine

नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

astrazeneca b.v prinses beatrixlaan 582 2595 bm den haag - quetiapinefumaraat 345,38 mg/stuk samenstelling overeenkomend met ; quetiapine 300 mg/stuk - tablet met verlengde afgifte - cellulose, microkristallijn (e 460(i)) ; hypromellose (e 464) ; hypromellose (release controlling polymer)(e 464) ; ijzeroxide geel (e 172) ; lactose 1-water ; macrogol 400 ; magnesiumstearaat (e 470b) ; titaandioxide (e 171) ; trinatriumcitraat 2-water (e 331), cellulose, microkristallijn (e 460) ; hypromellose (e 464) ; hypromellose (release controlling polymer)(e 464) ; ijzeroxide geel (e 172) ; lactose 1-water ; macrogol 400 ; magnesiumstearaat (e 470b) ; titaandioxide (e 171) ; trinatriumcitraat 2-water (e 331), - quetiapine

नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

astrazeneca b.v prinses beatrixlaan 582 2595 bm den haag - quetiapinefumaraat 460,5 mg/stuk samenstelling overeenkomend met ; quetiapine 400 mg/stuk - tablet met verlengde afgifte - cellulose, microkristallijn (e 460(i)) ; hypromellose (e 464) ; hypromellose (release controlling polymer)(e 464) ; lactose 1-water ; macrogol 400 ; magnesiumstearaat (e 470b) ; titaandioxide (e 171) ; trinatriumcitraat 2-water (e 331), cellulose, microkristallijn (e 460) ; hypromellose (e 464) ; hypromellose (release controlling polymer)(e 464) ; lactose 1-water ; macrogol 400 ; magnesiumstearaat (e 470b) ; titaandioxide (e 171) ; trinatriumcitraat 2-water (e 331), - quetiapine

नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

astrazeneca b.v prinses beatrixlaan 582 2595 bm den haag - quetiapinefumaraat 57,56 mg/stuk samenstelling overeenkomend met ; quetiapine 50 mg/stuk - tablet met verlengde afgifte - cellulose, microkristallijn (e 460(i)) ; hypromellose (e 464) ; hypromellose (release controlling polymer)(e 464) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; lactose 1-water ; macrogol 400 ; magnesiumstearaat (e 470b) ; titaandioxide (e 171) ; trinatriumcitraat 2-water (e 331), cellulose, microkristallijn (e 460) ; hypromellose (e 464) ; hypromellose (release controlling polymer)(e 464) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; lactose 1-water ; macrogol 400 ; magnesiumstearaat (e 470b) ; titaandioxide (e 171) ; trinatriumcitraat 2-water (e 331), - quetiapine

यूरोपीय संघ - डच - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateronacetaat - prostaatnoplasma - endocriene therapie - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

यूरोपीय संघ - डच - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - prostaatnoplasma - endocriene therapie - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

यूरोपीय संघ - डच - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastische middelen - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

यूरोपीय संघ - डच - EMA (European Medicines Agency)

bayer ag - darolutamide - de prostaat tumoren, castratie-resistente - endocriene therapie - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.

यूरोपीय संघ - डच - EMA (European Medicines Agency)

mylan ireland limited - abirateronacetaat - prostaatnoplasma - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

kaliumchloride (e 508) 0,0466 g/stuk ; macrogol 3350 13,125 g/stuk ; natriumchloride 0,3507 g/stuk ; natriumwaterstofcarbonaat (e 500 (ii)) 0,1785 g/stuk - poeder voor drank - arabische gom (e 414) ; aspartaam (e 951) ; butylhydroxyanisol (e 320) ; citroensmaakstof ; citroenzuur 0-water (e 330) ; maltodextrine ; sinaasappelsmaakstof ; sucralose (e 955) ; tocoferol, alfa (optische rotatie onbekend), arabische gom (e 414) ; aspartaam (e 951) ; butylhydroxyanisol (e 320) ; citroensmaakstof ; citroenzuur 0-water (e 330) ; maltodextrine ; sinaasappelsmaakstof ; sucralose (e 955) ; tocopherol, alpha (optical rotation unknown)